Rehmannia

Catalpol (the primary iridoid glycoside in Rehmannia glutinosa) reduces blood glucose via AMPK pathway activation, improved insulin secretion from pancreatic beta cells, and enhanced glucose uptake. Rehmannia polysaccharides also lower blood glucose, total cholesterol, and triglycerides in diabetic animal models by increasing islet insulin content. When combined with antidiabetic medications, additive hypoglycemic effects create risk of hypoglycemia, particularly relevant for insulin and sulfonylureas.

Monitor blood glucose closely when Rehmannia glutinosa is co-administered with antidiabetic drugs. Advise patients to check fasting glucose more frequently when starting Rehmannia. Reduce sulfonylurea or insulin dose under medical supervision if hypoglycemia occurs. Stop at least 2 weeks before surgery.

Rehmannia glutinosa extracts demonstrate antiplatelet and anticoagulant effects in preclinical studies. Acteoside and phenylpropanoid glycosides inhibit platelet aggregation and reduce blood viscosity. Pharmacodynamic synergism with anticoagulant/antiplatelet drugs increases bleeding risk. The herb has traditional indications for hemostasis, suggesting it modulates coagulation pathways bidirectionally depending on dose and preparation.

Monitor INR in warfarin users who start or stop Rehmannia preparations. Advise patients on antiplatelet therapy about increased bleeding risk. Discontinue at least 2 weeks before elective surgery. Monitor for unusual bruising or prolonged wound bleeding.

Rehmannia glutinosa modulates cytokine pathways (inhibits TNF-alpha and IL-1 secretion) and possesses immunomodulatory activity. In TCM practice it is sometimes combined with corticosteroids to reduce side effects. However, pharmacodynamic antagonism is possible: Rehmannia may attenuate corticosteroid-mediated immunosuppression, potentially reducing drug efficacy in organ transplant or severe autoimmune conditions requiring strong immunosuppression.

In transplant patients or those requiring strict immunosuppression, consult immunology/transplant team before using Rehmannia. In patients managed with prednisone for inflammatory conditions, monitor for signs of reduced drug effect. The potential benefit in mitigating steroid side effects should be weighed against immunosuppression antagonism.

Rehmannia glutinosa polysaccharides and iridoid glycosides lower blood pressure and reduce vascular inflammation in preclinical models. A clinical study found that combining Rehmannia acteosides with the ARB irbesartan in patients with primary chronic glomerulonephritis provided additive renal-protective and blood pressure-lowering effects beyond irbesartan alone, improving kidney function and reducing disease progression. Additive hypotension risk exists when combined with antihypertensives.

Monitor blood pressure periodically when Rehmannia is added to antihypertensive regimens. The combination may offer renal-protective synergy with ARBs or ACE inhibitors in CKD patients, but additive hypotension requires monitoring, especially at initiation. Educate patients on hypotension symptoms (dizziness, lightheadedness).

Rehmannia glutinosa exerts immunomodulatory activity including NK cell activation, T-cell regulation, and cytokine modulation. This may interfere with immunosuppressive drug regimens in organ transplant patients. Rehmannia polysaccharides activate macrophages and natural killer cells; this immunostimulation could counteract calcineurin inhibitor immunosuppression or trigger rejection episodes. Limited pharmacokinetic data exists for direct CYP interactions with immunosuppressants.

Use with caution in organ transplant patients. Monitor immunosuppressant levels and signs of rejection or over-immunosuppression. Disclose all herbal supplement use to the transplant team. Rehmannia is not recommended without specialist guidance in the post-transplant setting.